Wall Street is looking for $1.02 billion in 2024. EBS stock is up 57% as of Thursday morning, with nearly 5 million shares traded. That’s well above its daily average of about 3.1 million shares.

In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent ...

Equities research analysts at HC Wainwright issued their Q1 2025 earnings estimates for shares of Emergent BioSolutions in a report released on Tuesday, March 4th. HC Wainwright analyst R. Selvaraju ...

One of the biggest stories of last week was how Emergent BioSolutions Inc. ( NYSE:EBS ) shares plunged 20% in the ...

To identify new genetic modifiers for epidermolysis bullosa simplex (EBS), a team led by scientists at Tel Aviv Medical Center performed exome sequencing of 195 patients with EBS from 90 different ...

New York State Common Retirement Fund boosted its position in shares of Emergent BioSolutions Inc. (NYSE:EBS – Free Report) by 41.7% during the 4th quarter, according to the company in its most recent ...

Despite a dip in Q4 revenue, Emergent BioSolutions Inc (EBS) showcases significant profitability improvements and strategic positioning for future growth.